-
近年来高龄女性在不孕人群中的比例逐渐增加,女性生育力的评估成为不孕女性选择合适受孕方式及提高受孕成功率的关键,而卵巢储备功能的评估是女性生育力评估的核心内容[1]。目前临床上常采用年龄、性激素检测[主要包括卵泡刺激素(follicle stimulating hormone,FSH)、雌二醇(estradiol,E2)、促黄体生成素(luteinizing hormone,LH)等血清学指标]、卵巢刺激试验以及卵巢超声检查等对女性卵巢储备功能进行评估[2]。但上述各项评估方法也有自身局限性,如无法提前预知生育能力下降、敏感度和/或特异度较差等,往往无法正确评估病人的最佳治疗时间[3]。近年采用的抗苗勒氏管激素(anti-Müllerian hormone,AMH)检测可实现卵巢储备功能的准确评估,进而弥补传统激素检测的缺陷[4-5]。本研究采用回顾性分析,探讨AMH联合FSH技术对拟行辅助生殖技术高龄妇女卵巢储备功能的评估价值。现作报道。
-
3组病人年龄、AMH、FSH、AFC、E2及LH间差异均有统计学意义(P < 0.01);且相较于正常组,DOR组与POF组年龄、FSH及LH均明显增加,AMH、AFC及E2均明显降低(P < 0.01);而相较于DOR组,POF组年龄、FSH及LH均更高,AMH、AFC及E2均更低(P < 0.05~P < 0.01)。3组PRL、P水平间差异均无统计学意义(P>0.05)(见表 1)。
分组 n 年龄/岁 AMH/(ng/mL) FSH/(U/L) AFC/个 E2/(pg/mL) PRL/(nmol/L) LH/(IU/L) P/(ng/mL) 正常组 51 36.26±4.39 4.03±1.75 6.19±1.34 7.63±1.23 71.68±11.45 0.54±0.19 4.22±0.91 1.36±0.69 DOR组 46 39.31±4.76** 0.94±0.23** 16.52±3.03** 2.45±0.79** 58.34±9.03** 0.57±0.22 6.67±1.48** 1.49±0.75 POF组 42 42.83±4.91**## 0.39±0.11**# 67.12±11.25**## 0.18±0.03**## 37.15±6.28**## 0.49±0.17 32.37±4.88**## 1.46±0.72 F — 22.75 161.08 1 115.05 904.2 158.6 1.88 1 309.18 0.44 P — < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 >0.05 < 0.01 >0.05 MS组内 — 21.850 1.147 42.418 0.763 87.069 0.038 8.209 0.517 q检验:与正常组比较**P < 0.01;与DOR组比较#P < 0.05, ##P < 0.01 表 1 3组病人年龄及卵巢功能相关指标比较(x±s)
-
相关分析结果显示,AMH与AFC、E2均呈明显正相关关系(P < 0.01),与年龄、FSH、LH均呈明显负相关关系(P < 0.01);FSH与年龄、LH均呈正相关关系(P < 0.05和P < 0.01),与AFC、E2均呈明显负相关关系(P < 0.01)。而AMH、FSH与PRL、P均无明显相关关系(P>0.05)(见表 2)。
项目 年龄 AMH FSH AFC E2 PRL LH P AMH -0.643** — -0.935** 0.809** 0.728** 0.221 -0.892** -0.173 FSH 0.587* -0.935** — -0.833** -0.695** -0.244 0.861** 0.183 *P < 0.05,**P < 0.01 表 2 AMH、FSH与各指标的相关性分析(r)
-
对年龄、AMH、FSH单独或联合诊断卵巢储备功能异常的价值分别进行ROC分析,结果显示,年龄、AMH及FSH诊断卵巢储备功能异常的临界值分别为36.25岁、1.27 ng/mL、8.11 U/L,三项联合诊断卵巢储备功能异常的AUC值为0.932,灵敏度93.18%,特异度94.11%,PPV为96.47%,NPV为88.89%,检出率96.59%,均高于单项检测(P < 0.05)(见表 3)。
项目 临界值 AUC(95%CI) 灵敏度/% 特异度/% PPV/% NPV/% 检出率/% 年龄/岁 36.25 0.579(0.525~0.687) 70.45 82.35 87.32 61.76 63.64 AMH/(ng/mL) 1.27 0.736(0.604~0.859) 81.82 78.43 86.75 71.43 84.09 FSH/(U/L) 8.11 0.641(0.518~0.722) 79.55 64.71 79.55 64.71 77.27 联合检测 — 0.932(0.757~0.983) 93.18*#△ 94.11*#△ 96.47*#△ 88.89*#△ 96.59*#△ 与年龄比较*P < 0.05;与AMH检测比较#P < 0.05;与FSH检测比较△P < 0.05 表 3 年龄、AMH及FSH对卵巢储备功能异常的评估价值
-
妊娠组AMH、E2均明显高于非妊娠组(P < 0.01和P < 0.05),FSH、LH均明显低于未妊娠组(P < 0.01)(见表 4)。
分组 n 年龄/岁 AMH/(ng/mL) FSH/(U/L) AFC/个 E2/(pg/mL) PRL/(nmol/L) LH/(IU/L) P/(ng/mL) 妊娠组 37 35.87±4.31 4.48±1.86 5.26±1.15 7.82±1.26 75.64±12.15 0.52±0.17 3.91±0.82 1.34±0.67 未妊娠组 14 36.71±4.56 2.29±1.52 9.33±1.47 7.57±1.19 66.49±10.93 0.56±0.20 4.87±1.17 1.39±0.72 t — 0.61 3.93 10.44 0.64 2.46 0.71 3.30 0.23 P — >0.05 < 0.01 < 0.01 >0.05 < 0.05 >0.05 < 0.01 >0.05 表 4 妊娠组与未妊娠组年龄及卵巢功能相关指标比较(x±s)
AMH联合FSH检测对拟行辅助生殖技术高龄妇女卵巢储备功能的评估价值
The value of AMH combined with FSH detection in the evaluation of ovarian reserve function in elderly women scheduled by assisted reproductive technology
-
摘要:
目的探讨抗苗勒氏管激素(AMH)联合促卵泡刺激素(FSH)检测对高龄拟行辅助生殖技术病人的卵巢储备功能的评估价值。 方法回顾性分析高龄拟行辅助生殖技术病人139例的临床资料,所有病人年龄>35岁。参照2017年波塞冬卵巢低反应分组标准,按照卵巢储备功能检查结果将病人分为正常组51例、卵巢功能减退(DOR)组46例及卵巢早衰(POF)组42例;根据1年内是否成功受孕将正常组病人分为妊娠组37例及未妊娠组14例。比较各组病人卵巢功能相关评定指标,采用受试者工作特征曲线评价病人年龄、AMH、FSH单独或联合诊断对卵巢储备功能异常的评估价值。 结果DOR组和POF组年龄、FSH及促黄体生成素(LH)均明显高于正常组,AMH、窦卵泡计数(AFC)及雌二醇(E2)均明显低于正常组(P < 0.01);POF组年龄、FSH及LH均高于DOR组,AMH、AFC及E2均低于DOR组(P < 0.05~P < 0.01);3组催乳素、孕酮水平间差异均无统计学意义(P>0.05)。相关分析结果显示,AMH与AFC、E2均呈明显正相关关系(P < 0.01),与年龄、FSH、LH均呈明显负相关关系(P < 0.01);FSH与年龄、LH均呈正相关关系(P < 0.05和P < 0.01),与AFC、E2均呈明显负相关关系(P < 0.01);而AMH、FSH与催乳素、孕酮均无明显相关关系(P>0.05)。年龄、AMH及FSH诊断卵巢储备功能异常的临界值分别为36.25岁、1.27 ng/mL、8.11 U/L,三项联合诊断卵巢储备功能异常的AUC值为0.932,灵敏度93.18%,特异度94.11%,阳性似然比为96.47%,阴性似然比为88.89%,检出率96.59%,均高于单项检测(P < 0.05)。按照1年内是否成功受孕,将卵巢储备功能正常组病人分为妊娠组37例及未妊娠组14例。结果显示,妊娠组AMH、E2均明显高于非妊娠组(P < 0.01和P < 0.05),FSH、LH均明显低于未妊娠组(P < 0.01)。 结论AMH、FSH是评估高龄拟行辅助生殖技术病人卵巢储备功能的有效指标,AMH联合FSH检测技术有望替代传统的卵巢储备功能评估体系。 Abstract:ObjectiveTo investigate the value of anti-Miillerian hormone(AMH) combined with follicle stimulating hormone(FSH) in the evaluation of ovarian reserve function in elderly women scheduled by assisted reproductive technology. MethodsThe clinical data of 139 elderly patients(aged >35 years old) scheduled by assisted reproductive technology were retrospectively analyzed.According to the 2017 Poseidon poor ovarian response grouping criteria and ovarian reserve function test results, the patients were divided into normal group(n=51), diminished ovarian reserve(DOR) group(n=46) and premature ovarian failure(POF) group(n=42).According to the success of pregnancy within 1 year, the normal group was subdivided into the pregnant group(n=37) and non-pregnant group(n=14).The ovarian function-related assessment indexes were compared among all groups.The receiver operating characteristic curve(ROC) was used to evaluate the value of age, AMH and FSH alone or combined in the diagnosis of ovarian reserve dysfunction. ResultsThe age, FSH and LH in DOR and POF groups were significantly higher than those in normal group, while the AMH, AFC and E2 were significantly lower than those in normal group(P < 0.01).The age, FSH and LH in POF group were higher than those in DOR group, and the AMH, AFC and E2 in POF group were lower than those in DOR group(P < 0.05 to P < 0.01).The differences of the levels of PRL and P among three groups were not statistically significant(P>0.05).The results of correlation analysis showed that the AMH was positively correlated with AFC and E2(P < 0.01), and negatively correlated with the age, FSH and LH(P < 0.01).The FSH was positively correlated with age and LH(P < 0.01 and P < 0.05), and negatively correlated with AFC and E2(P < 0.01).There was not significant correlation among AMH, FSH, PRL and P(P>0.05).The critical values of age, AMH and FSH in the diagnosis of ovarian reserve dysfunction were 36.25 years old, 1.27 ng/mL and 8.11 U/L, respectively.The AUC value, sensitivity, specificity, PPV and NPV of three combination detection in the diagnosis of ovarian reserve dysfunction were 0.932, 93.18%, 94.11%, 96.47%, 88.89% and 96.59%, respectively, which were higher than those of single detection(P < 0.05).The levels of AMH and E2 in pregnant group were significantly higher than those in non-pregnant group(P < 0.01 and P < 0.05), while the levels of FSH and LH in pregnant group were significantly lower than those in non-pregnant group(P < 0.01). ConclusionsThe AMH and FSH are the effective indexes to evaluate the ovarian reserve function in elderly patients scheduled by assisted reproductive technology.The AMH combined with FSH detection technology can effectively replace the traditional evaluation system of ovarian reserve function. -
表 1 3组病人年龄及卵巢功能相关指标比较(x±s)
分组 n 年龄/岁 AMH/(ng/mL) FSH/(U/L) AFC/个 E2/(pg/mL) PRL/(nmol/L) LH/(IU/L) P/(ng/mL) 正常组 51 36.26±4.39 4.03±1.75 6.19±1.34 7.63±1.23 71.68±11.45 0.54±0.19 4.22±0.91 1.36±0.69 DOR组 46 39.31±4.76** 0.94±0.23** 16.52±3.03** 2.45±0.79** 58.34±9.03** 0.57±0.22 6.67±1.48** 1.49±0.75 POF组 42 42.83±4.91**## 0.39±0.11**# 67.12±11.25**## 0.18±0.03**## 37.15±6.28**## 0.49±0.17 32.37±4.88**## 1.46±0.72 F — 22.75 161.08 1 115.05 904.2 158.6 1.88 1 309.18 0.44 P — < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 >0.05 < 0.01 >0.05 MS组内 — 21.850 1.147 42.418 0.763 87.069 0.038 8.209 0.517 q检验:与正常组比较**P < 0.01;与DOR组比较#P < 0.05, ##P < 0.01 表 2 AMH、FSH与各指标的相关性分析(r)
项目 年龄 AMH FSH AFC E2 PRL LH P AMH -0.643** — -0.935** 0.809** 0.728** 0.221 -0.892** -0.173 FSH 0.587* -0.935** — -0.833** -0.695** -0.244 0.861** 0.183 *P < 0.05,**P < 0.01 表 3 年龄、AMH及FSH对卵巢储备功能异常的评估价值
项目 临界值 AUC(95%CI) 灵敏度/% 特异度/% PPV/% NPV/% 检出率/% 年龄/岁 36.25 0.579(0.525~0.687) 70.45 82.35 87.32 61.76 63.64 AMH/(ng/mL) 1.27 0.736(0.604~0.859) 81.82 78.43 86.75 71.43 84.09 FSH/(U/L) 8.11 0.641(0.518~0.722) 79.55 64.71 79.55 64.71 77.27 联合检测 — 0.932(0.757~0.983) 93.18*#△ 94.11*#△ 96.47*#△ 88.89*#△ 96.59*#△ 与年龄比较*P < 0.05;与AMH检测比较#P < 0.05;与FSH检测比较△P < 0.05 表 4 妊娠组与未妊娠组年龄及卵巢功能相关指标比较(x±s)
分组 n 年龄/岁 AMH/(ng/mL) FSH/(U/L) AFC/个 E2/(pg/mL) PRL/(nmol/L) LH/(IU/L) P/(ng/mL) 妊娠组 37 35.87±4.31 4.48±1.86 5.26±1.15 7.82±1.26 75.64±12.15 0.52±0.17 3.91±0.82 1.34±0.67 未妊娠组 14 36.71±4.56 2.29±1.52 9.33±1.47 7.57±1.19 66.49±10.93 0.56±0.20 4.87±1.17 1.39±0.72 t — 0.61 3.93 10.44 0.64 2.46 0.71 3.30 0.23 P — >0.05 < 0.01 < 0.01 >0.05 < 0.05 >0.05 < 0.01 >0.05 -
[1] 刘曼曼, 管一春, 刘文霞, 等. 不同促排卵方案对卵巢储备功能减退患者体外受精-胚胎移植结局的影响[J]. 新乡医学院学报, 2019, 36(6): 529. [2] 孙晓华, 李红梅. 腹腔镜卵巢囊肿剥除术中的两种止血方式对患者卵巢储备功能的影响[J]. 贵州医科大学学报, 2019, 44(10): 1. [3] KARLBERG S, TⅡTINEN A, ALFTHAN H, et al. Premature ovarian insufficiency and early depletion of the ovarian reserve in the monogenic Mulibrey nanism disorder[J]. Hum Reprod, 2018, 33(7): 1254. doi: 10.1093/humrep/dey103 [4] 闵爱萍, 吴羽. 腹腔镜卵巢子宫内膜异位囊肿剥除术联合亮丙瑞林对卵巢子宫内膜异位囊肿患者卵巢储备功能的影响[J]. 中国医药导报, 2018, 15(18): 68. [5] 郭小玲. 腹腔镜下卵巢子宫内膜异位囊肿剔除对患者卵巢储备功能的影响研究[J]. 中国医药科学, 2016, 6(10): 57. [6] VINCENTELLI C, MARANINCHI M, VALERO R, et al. One-year impact of bariatric surgery on serum anti-Mullerian-hormone levels in severely obese women[J]. J Assist Reprod Genet, 2018, 35(7): 1317. doi: 10.1007/s10815-018-1196-3 [7] GLUCK O, TAMAYEV L, TOREM M, et al. The impact of salpingectomy on anti-mullerian hormone levels and ovarian response of in vitro fertilization patients[J]. Isr Med Assoc J, 2018, 20(8): 509. [8] HAMZA RT, MIRA MF, HAMED AI, et al. Anti-Mullerian hormone levels in patients with turner syndrome: Relation to karyotype, spontaneous puberty, and replacement therapy[J]. Am J Med Genet A, 2018, 176(9): 1929. doi: 10.1002/ajmg.a.40473 [9] 徐秋红, 吴斯瑶, 孙国丽, 等. 经阴道三维超声自动容积测量技术联合女性基础激素及抗苗勒管激素测定在卵巢储备功能评估中的应用价值[J]. 中国医学创新, 2017, 14(35): 59. doi: 10.3969/j.issn.1674-4985.2017.35.016 [10] 庄丽丽, 丛建香, 戴皇冠, 等. 国产注射用重组人卵泡刺激素在不同卵巢储备功能患者长方案控制性超促排卵中的疗效观察[J]. 中国实用妇科与产科杂志, 2019, 35(8): 924. [11] VERMEULEN RFM, BEURDEN M, GAARENSTROOM KN, et al. Does anti-Mullerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy: a prospective observational study[J]. Climacteric, 2018, 21(6): 574. doi: 10.1080/13697137.2018.1512965 [12] 高照猛, 徐建, 张磊, 等. 抗苗勒管激素水平评价生育期女性类风湿关节炎患者卵巢储备功能的临床意义[J]. 中国现代医生, 2018, 56(14): 21. [13] ZHONG Y, LIN Y, CHENG XQ, et al. GnRHa for ovarian protection and the association between AMH and ovarian function during adjuvant chemotherapy for breast cancer[J]. J Cancer, 2019, 10(18): 4278. doi: 10.7150/jca.31859 [14] CANDIANI M, OTTOLINA J, POSADZKA E, et al. Assessment of ovarian reserve after cystectomy versus 'one-step' laser vaporization in the treatment of ovarian endometrioma: a small randomized clinical trial[J]. Hum Reprod, 2018, 33(12): 2205. [15] XUE C, WEI WW, SUN P, et al. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer[J]. Breast Cancer Res Tr, 2019, 173(3): 619. doi: 10.1007/s10549-018-4997-2 [16] 李再仪, 游泽山, 罗宋, 等. 抗苗勒管激素在腹膜型子宫内膜异位症患者卵巢储备功能评估中的价值研究[J]. 新医学, 2018, 49(2): 129. doi: 10.3969/j.issn.0253-9802.2018.02.012 [17] WANG SY, WANG S. Anti-Mullerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients[J]. J Peking Univ Health Sci, 2019, 51(3): 536. [18] CHEN R, XIONG W, LUO XY, et al. Association of gene polymorphisms in the anti-Mullerian hormone signalling pathway with ovarianfunction: a systematic review and meta-analysis[J]. Reprod BioMed Online, 2019, 39(3): 513. doi: 10.1016/j.rbmo.2019.04.010 [19] 曾辛, 段颖卿, 徐静, 等. 卵巢子宫内膜异位囊肿患者术前应用促性腺激素释放激素激动剂的临床研究[J]. 中国现代医学杂志, 2018, 28(13): 109. doi: 10.3969/j.issn.1005-8982.2018.13.020 [20] 王雪, 李秋圆, 张少娣, 等. 卵巢储备功能评估指标对高卵泡刺激素人群体外受精-胚胎移植结局预测的研究[J]. 中华生殖与避孕杂志, 2018, 38(12): 1009. [21] IWASE A, OSUKA S, GOTO M, et al. Clinical application of serum anti-Mullerian hormone as an ovarian reserve marker: A review of recent studies[J]. J Obstet Gynaecol Res, 2018, 44(6): 998. doi: 10.1111/jog.13633 [22] 王茜, 吴敏, 孙健. 血清抗苗勒氏管激素早期预测不孕症妇女妊娠结局的临床研究[J]. 湖南师范大学学报(医学版), 2019, 16(2): 22. [23] 唐移忠, 许秀玲, 闫冬梅. 血清基础抗苗勒管激素和抑制素B与卵巢储备功能的关系及其临床价值分析[J]. 中国医药科学, 2018, 8(19): 214. doi: 10.3969/j.issn.2095-0616.2018.19.061 [24] 郑建波, 李艳, 夏尊恩. 联合检测抗苗勒管激素和性激素对卵巢储备功能评估的临床价值[J]. 分子诊断与治疗杂志, 2018, 10(6): 400. doi: 10.3969/j.issn.1674-6929.2018.06.009